Literature DB >> 22544940

Direct in vivo evidence of CD4+ T cell requirement for CTL response and memory via pMHC-I targeting and CD40L signaling.

Khawaja Ashfaque Ahmed1, Lu Wang, Manjunatha Ankathatti Munegowda, Sean J Mulligan, Sean Mulligan, John R Gordon, Philip Griebel, Jim Xiang.   

Abstract

CD4(+) T cell help contributes critically to DC-induced CD8(+) CTL immunity. However, precisely how these three cell populations interact and how CD4(+) T cell signals are delivered to CD8(+) T cells in vivo have been unclear. In this study, we developed a novel, two-step approach, wherein CD4(+) T cells and antigen-presenting DCs productively engaged one another in vivo in the absence of cognate CD8(+) T cells, after which, we selectively depleted the previously engaged CD4(+) T cells or DCs before allowing interactions of either population alone with naïve CD8(+) T cells. This protocol thus allows us to clearly document the importance of CD4(+) T-licensed DCs and DC-primed CD4(+) T cells in CTL immunity. Here, we provide direct in vivo evidence that primed CD4(+) T cells or licensed DCs can stimulate CTL response and memory, independent of DC-CD4(+) T cell clusters. Our results suggest that primed CD4(+) T cells with acquired pMHC-I from DCs represent crucial "immune intermediates" for rapid induction of CTL responses and for functional memory via CD40L signaling. Importantly, intravital, two-photon microscopy elegantly provide unequivocal in vivo evidence for direct CD4-CD8(+) T cell interactions via pMHC-I engagement. This study corroborates the coexistence of direct and indirect mechanisms of T cell help for a CTL response in noninflammatory situations. These data suggest a new "dynamic model of three-cell interactions" for CTL immunity derived from stimulation by dissociated, licensed DCs, primed CD4(+) T cells, and DC-CD4(+) T cell clusters and may have significant implications for autoimmunity and vaccine design.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544940     DOI: 10.1189/jlb.1211631

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  15 in total

Review 1.  CD8⁺ T Cell-Independent Immune-Mediated Mechanisms of Anti-Tumor Activity.

Authors:  G Elizabeth Pluhar; Christopher A Pennell; Michael R Olin
Journal:  Crit Rev Immunol       Date:  2015       Impact factor: 2.214

2.  Total CD3 T Cells Are Necessary and Sufficient to Induce Colitis in Immunodeficient Mice With Dendritic Cell-Specific Deletion of TGFbR2: A Novel IBD Model to Study CD4 and CD8 T-Cell Interaction.

Authors:  Deepa Rana Jamwal; Raji V Marati; Christy A Harrison; Monica T Midura-Kiela; Vanessa R Figliuolo Paz; David G Besselsen; Fayez K Ghishan; Pawel R Kiela
Journal:  Inflamm Bowel Dis       Date:  2020-01-06       Impact factor: 5.325

Review 3.  Mannose-6-phosphate receptor: a novel regulator of T cell immunity.

Authors:  Anjuman Ara; Khawaja Ashfaque Ahmed; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2018-05-16       Impact factor: 11.530

4.  Immediate Dysfunction of Vaccine-Elicited CD8+ T Cells Primed in the Absence of CD4+ T Cells.

Authors:  Nicholas M Provine; Rafael A Larocca; Malika Aid; Pablo Penaloza-MacMaster; Alexander Badamchi-Zadeh; Erica N Borducchi; Kathleen B Yates; Peter Abbink; Marinela Kirilova; David Ng'ang'a; Jonathan Bramson; W Nicholas Haining; Dan H Barouch
Journal:  J Immunol       Date:  2016-07-22       Impact factor: 5.422

5.  Differential requirements of cellular and humoral immune responses for Fv2-associated resistance to erythroleukemia and for regulation of retrovirus-induced myeloid leukemia development.

Authors:  Sachiyo Tsuji-Kawahara; Hiroyuki Kawabata; Hideaki Matsukuma; Saori Kinoshita; Tomomi Chikaishi; Mayumi Sakamoto; Yuri Kawasaki; Masaaki Miyazawa
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

6.  Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway.

Authors:  Rong Wang; Aizhang Xu; Xueying Zhang; Jie Wu; Andrew Freywald; Jianqing Xu; Jim Xiang
Journal:  Cell Mol Immunol       Date:  2016-06-06       Impact factor: 11.530

7.  A new dynamic model of three cell interactions for CTL responses.

Authors:  Khawaja Ashfaque Ahmed; Lu Wang; Jim Xiang
Journal:  Oncoimmunology       Date:  2012-11-01       Impact factor: 8.110

8.  Th cells promote CTL survival and memory via acquired pMHC-I and endogenous IL-2 and CD40L signaling and by modulating apoptosis-controlling pathways.

Authors:  Channakeshava Sokke Umeshappa; Yufeng Xie; Shulin Xu; Roopa Hebbandi Nanjundappa; Andrew Freywald; Yulin Deng; Hong Ma; Jim Xiang
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

9.  Regulatory B cells inhibit cytotoxic T lymphocyte (CTL) activity and elimination of infected CD4 T cells after in vitro reactivation of HIV latent reservoirs.

Authors:  Basile Siewe; Jennillee Wallace; Sonya Rygielski; Jack T Stapleton; Jeffrey Martin; Steven G Deeks; Alan Landay
Journal:  PLoS One       Date:  2014-04-16       Impact factor: 3.240

10.  Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.

Authors:  Kalpana Kalyanasundaram Bhanumathy; Bei Zhang; Khawaja Ashfaque Ahmed; Mabood Qureshi; Yufeng Xie; Min Tao; Xin Tan; Jim Xiang
Journal:  Int J Mol Sci       Date:  2014-03-31       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.